KPT-8602

DRUG2 trials

Sponsors

Karyopharm Therapeutics Inc, National Cancer Institute (NCI)

Conditions

Acute Myeloid Leukemia (AML)Higher-Risk Myelodysplastic Syndrome (HR-MDS)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Colorectal Cancer (mCRC)Myelodysplastic SyndromesNewly Diagnosed Intermediate/High-Risk MDSRelapsed/Refractory Multiple Myeloma (RRMM)

Phase 1

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

CompletedNCT02649790

Karyopharm Therapeutics IncAcute Myeloid Leukemia (AML), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Metastatic Castration-Resistant Prostate Cancer (mCRPC) +3

Start: 2016-01-31End: 2024-12-23Target: 277Updated: 2025-03-19

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

TerminatedNCT05918055

National Cancer Institute (NCI)Myelodysplastic Syndromes

Start: 2023-11-14End: 2025-03-12Updated: 2025-12-02

Related Papers

Exporting nuclear export inhibitors from hematologic to solid tumour malignancies

Clinical and Translational Discovery2024-07-29

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.

2022-08-0314 citations

Updated Efficacy of Eltanexor Monotherapy in Patients with Higher Risk Hypomethylating Myelodysplastic Syndrome Primary Refractory to Hypomethylating Agents

Blood2021-11-05

Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.

Journal of Clinical Oncology2021-05-205 citations

Abstract 4181: The XPO1 inhibitior, eltanexor, exhibits potent <i>in vivo</i> activity against a broad range of pediatric acute lymphoblastic leukemia subtypes

Cancer Research2020-08-152 citations

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Blood2019-11-135 citations

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-03-012 citations

P136 ELTANEXOR, AN EXPORTIN-1 INHIBITOR, RAPIDLY DECREASES INFLAMMATION AND IMPROVES OUTCOMES <i>IN VITRO</i> AND IN A DSS MODEL OF IBD

Inflammatory Bowel Diseases2019-02-01

Selective Inhibition of Nucleocytoplasmic Transport Overcomes Ruxolitinib Resistance in Myelofibrosis

Blood2017-12-07

Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma

Blood2016-12-028 citations